ROIVANT SCIENCES LTD
ROIVNASDAQTrading Snapshot
- Day Range
- $35.86 – $36.38
- 52-Week Range
- $14.86 – $42.50
- Volume
- $2.65B
- Avg Volume
- $2.15B
- Shares Outstanding
- 722.4M
- Next Earnings
- Nov 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $8M
- Last Q Revenue
- $1M
- P/E Ratio
- -97.0
- P/S Ratio
- 3536.3x
- EPS (TTM)
- $-0.37
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.4%
Why Investors Own ROIV
- ✓High-growth profile — revenue up +45.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 66% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ROIVANT SCIENCES LTD
ROIV
StockOtter · stockotter.spaceAbout ROIVANT SCIENCES LTD
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Roivant Sciences (NASDAQ: ROIV) CEO Matthew Gline outlined the company's priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant's IMVT-1402, and expansi
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Se
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Se
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells $196,236.12 in Stock
Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) Director Melissa Epperly sold 4,938 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $39.74, for a total
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants
LISRAYA's recent approval gives ROIV a nice commercial foundation, while additional indications could turn brepocitinib into a broader immunology franchise. ROIV's pulmonary asset with mosliciguat is also promising. This